Archive · 11 Jun 2025
Marksans Pharma Shares in Focus After Block Deals
OrbiMed sold a portion of its shares in Marksans Pharma through a block deal, resulting in a transaction valued at approximately ₹257 crore.
About 1.02 crore shares changed hands at an average price of ₹250 each.
The deal was initiated by OrbiMed Asia IV Mauritius FVCI Ltd, which previously held a 10.88% stake.
Marksans Pharma saw a significant increase in its consolidated net profit and revenue in the fourth quarter of FY25.
The stock closed lower on Tuesday, and has declined by nearly 20% in 2025.
OrbiMed sold a portion of its Marksans Pharma shares via a block deal.
Approximately 1.02 crore shares were traded.
The average share price was ₹250.
The total transaction value reached ₹257 crore.
Marksans Pharma's shares closed lower on Tuesday.
- Who
- OrbiMed Asia IV Mauritius FVCI Ltd and Marksans Pharma
- What
- OrbiMed sold a 2.27% stake in Marksans Pharma via block deals.
- When
- June 11, after a block deal
- Where
- India's stock exchange
- Why
- The article does not specify the exact reasons for the sale.
- Seller
- OrbiMed Asia IV Mauritius FVCI Ltd
- Stake Sold
- 2.27% (intended)
- Shares Traded
- 1.02 crore
- Average Price Per Share
- ₹250
- Total Transaction Value
- ₹257 crore
- Marksans Pharma Q4 FY25 Net Profit Increase
- 15.6% (YoY)
- Marksans Pharma Q4 FY25 Revenue Increase
- 26.5% (YoY)
- Share Price Change (Tuesday)
- ₹250, down 1.32%
